McKhann
G, Drachman
D, Folstein
M, Katzman
R, Price
D, Stadlan
EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;;34:939-- 944.
Blessed
G, Tomlinson
BE, Roth
M. The association between quantitative measures of dementia and senile changes in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;;114:797-- 811.
Lawton
M, Brody
E. Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist. 1969;;9:179-- 186.
Gelinas
I, Gauthier
L, McIntyre
M, Gauthier
S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999;;53:471-- 481.
Davis
KL, Marin
DB, Kane
R.
et al. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;;12:978-- 988.
Marin
DB, Dugue
M, Schmeidler
J.
et al. The Caregiver Activity Survey (CAS): longitudinal validation of an instrument that measures time spent caregiving for individuals with Alzheimer's disease. Int J Geriatr Psychiatry. 2000;;15:680-- 686.
Stern
Y, Albert
SM, Sano
M.
et al. Assessing patient dependence in Alzheimer's disease. J Gerontol. 1994;;49:M216-- M222.
Mulnard
RA, Cotman
CW, Kawas
C.
et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial: Alzheimer's Disease Cooperative Study. JAMA. 2000;;283:1007-- 1015.
Sano
M, Ernesto
C, Klauber
MR.
et al. Rationale and design of a multicenter study of selegiline and α-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer Dis Assoc Disord. 1996;;10:132-- 140.
Sano
M, Ernesto
C, Thomas
RG.
et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997;;336:1216-- 1222.
Albert
SM, Sano
M, Marder
K.
et al. Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology. 1997;;49:38-- 43.
Knopman
DS, Berg
JD, Thomas
R, Grundman
M, Thal
LJ, Sano
M. Nursing home placement is related to dementia progression: experience from a clinical trial. Neurology. 1999;;52:714-- 718.
Bird
M, Llewellyn-Jones
R, Smithers
H.
et al. Challenging behaviours in dementia: a project at Hornsby Ku-Ring-Gai Hospital. Aust J Ageing. 1998;;17:10-- 15.
Stern
Y, Jacobs
DM. Preliminary findings from the Predictors Study: utility of clinical signs for predicting disease course. Alzheimer Dis Assoc Disord. 1995;;9(suppl 1):S14-- S18.
Stern
Y, Albert
SM, Brandt
J.
et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology. 1994;;44:2300-- 2307.
Zanetti
O, Frisoni
GB, Rozzini
L, Bianchetti
A, Trabucchi
M. Validity of Direct Assessment of Functional Status as a tool for measuring Alzheimer's disease severity. Age Ageing. 1998;;27:615-- 622.
Albert
SM, Marks
J, Barrett
V, Gurland
B. Home health care and quality of life of patients with Alzheimer's disease. Am J Prev Med. 1997;;13(suppl 2):63-- 68.
Bavazzano
A, Magnolfi
SU, Calvani
D.
et al. Functional evaluation of Alzheimer patients during clinical trials: a review. Arch Gerontol Geriatr. 1998;;26(suppl 6):27-- 32.
Bullock
R, Passmore
P, Wilkinson
D, Howard
R, Jones
R. Effectiveness of rivastigmine in Alzheimer's disease: participation in trials should be based on clinical uncertainty, not enforcement. BMJ. 2000;;320:511-- 512.
Gauthier
S, Bodick
N, Erzigkeit
E.
et al. Activities of daily living as an outcome measure in clinical trials of dementia drugs: position paper from the International Working Group of Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;;11(suppl 3):6-- 7.
Lewis
CB, Lindsay
T, Scott
C. Functional assessment in the psychosocial realm. Top Geriatr Rehabil. 1996;;11:64-- 83.
White
H, Clipp
EC, Hanlon
JT, Schmader
K. The role of the caregiver in the drug-treatment of dementia. CNS Drugs. 1995;;4:58-- 67.
Stern
Y, Folstein
M, Albert
M.
et al. Multi-center study of predictors of disease course in Alzheimer's disease (the "Predictors Study"), I: study design, cohort description and intersite comparisons. Alzheimer Dis Assoc Disord. 1993;;7:3-- 21.
Richards
M, Folstein
M, Albert
M.
et al. Multi-center study of predictors of disease course in Alzheimer's disease (the "Predictors Study"), II: baseline findings. Alzheimer Dis Assoc Disord. 1993;;7:22-- 32.
Folstein
MF, Folstein
SE, McHugh
PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;;12:189-- 198.
Stern
Y, Sano
M, Paulson
J, Mayeux
R. Modified Mini-Mental State Examination: validity and reliability. Neurology. 1982;;37(suppl 1):179.
Stern
Y, Mayeux
R, Hesdorfer
D, Sano
M. Measurement and prediction of functional change in Alzheimer's disease. Neurology. 1990;;40:8-- 14.
Liang
KY, Zeger
SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;;73:13-- 22.
Mayeux
R, Stern
Y, Spanton
S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology. 1985;;35:453-- 461.
Marin
DB, Green
CR, Schmeidler
J.
et al. Noncognitive disturbances in Alzheimer's disease: frequency, longitudinal course, and relationship to cognitive symptoms. J Am Geriatr Soc. 1997;;45:1331-- 1338.
Morris
JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;;43:2412-- 2414.